A Study of Chidamide With AZA in MRD Positive AML After Transplant

acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

1. Patients diagnosed with AML (diagnostic criteria refer to WHO2016 criteria, except M3) can detect small residual lesions (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT);
2. ≥18 years old;
3. ECOG≤3;
4. lifespan≥3 months;
5. Take contraceptive measures;
6. Sign informed consent.

Exclusion Criteria:

1. Allergic to the study drug;
2. A gastrointestinal condition that prevents oral medication;
3. active infection;
4. Dysfunction of vital organs;
5. other malignancies;
6. HIV infection;
7. HBV or HCV;
8. The QT interval is prolonged;
9. Pregnant or lactating women;
10. Is participating in other clinical studies;
11. The researchers did not consider it appropriate to participate in this study.

• DERIVEDLing W, Wu P, Wu S, Luo C, Huang L, Chen X, Liang X, Li Z, Xu R, Tan J, Wang J, Lai P, Du X, Weng J. MRD-driven HDACi-based therapy post-transplant: a real-world study in high-risk acute myeloid leukemia. Ann Hematol. 2026 Jul 13. doi: 10.1007/s00277-026-07117-7. Online ahead of print. PMID 42439986